Catheter Precision, Inc. (VTAK)

Catheter Precision, Incorporated designs medical devices that help cardiologists visualize and treat dangerous heart rhythms. The company’s tools target one specific surgical specialty: cardiac electrophysiology, which deals with disorders of the heart’s electrical system — irregular beating patterns that can lead to stroke, heart failure, or sudden death. A customer for Catheter Precision is a hospital electrophysiology lab, and what they are really buying is a better view inside the beating heart and more reliable tools for stopping arrhythmias once those dangerous rhythms are identified.

What Catheter Precision Makes

The company’s flagship product is the VIVO System — a 3D imaging technology that shows electrophysiologists a real-time, detailed map of the heart’s electrical activity during an ablation procedure. Ablation is the treatment for many arrhythmias: a catheter is threaded into the heart, and the tip is used to heat or freeze the tissue that is misfiring and causing the irregular rhythm. The catch is that arrhythmia substrate can be hard to pinpoint. If the surgeon cannot see exactly where the problem tissue is, the ablation fails and the patient returns with the same problem.

VIVO’s job is to answer the question: where exactly is the tissue causing trouble? By providing a 3D map of electrical activity in real time, VIVO helps electrophysiologists identify the arrhythmia source quickly and ablate it accurately. The system reduces procedure time and the risk of hitting healthy tissue by accident.

Catheter Precision also makes LockeT, a suture-retention device designed to hold catheters in place during electrophysiology procedures. LockeT’s value is simpler and more mechanical: it prevents catheters from sliding or moving during long procedures, which can prolong surgery and increase the risk of complications.

The Business Picture

Catheter Precision’s core business has been capital-constrained from inception. Medical device companies must navigate FDA approval, which is expensive and slow. Both VIVO and LockeT have cleared the FDA and are approved for sale in the United States. VIVO also holds CE marking in Europe, and the company has secured orders from hospitals in Hungary, Croatia, Switzerland, and South Africa.

Despite regulatory approval, Catheter Precision has struggled to scale sales. The company reported very modest revenue of around 819 thousand dollars in 2025, a steep increase from prior years but still tiny by industry standards. The company is burning cash, reporting net losses in the millions. The electrophysiology market is real — cardiac arrhythmias affect millions of people globally — but penetrating it requires field sales teams, clinical support, and competitive pricing. Catheter Precision, as a small-cap public company, has had trouble mustering those resources.

In 2025, the company made a dramatic strategic shift: it acquired Flyte, a small air-mobility operator. Flyte operates regional electric aircraft and runs a revenue-generating aviation business. This move seemed to signal that Catheter Precision’s leadership had lost confidence in the cardiac device business, or at least viewed it as a long-term, low-probability bet. The company began a phased transition away from cardiac electrophysiology.

The Pivot

In April 2026, Catheter Precision engaged a strategic advisor to market the sale of its entire cardiac electrophysiology business — that is, VIVO, LockeT, FDA approvals, regulatory files, and all related assets. The stated goal was to monetize the legacy medical business and redirect capital and management focus toward Flyte, the aviation company.

This is a reversal of the company’s original thesis. Catheter Precision was founded to address a genuine medical need — the high stakes and technical difficulty of treating arrhythmias. The VIVO system represents real clinical innovation. But medical device companies need scale, persistent capital, and experienced sales teams to succeed. Catheter Precision did not have those, and rather than build them or raise the substantial capital required, the company chose to offload the medical business entirely.

For customers who have already adopted VIVO or LockeT, this creates uncertainty. Will the buyer maintain clinical support, develop new features, or commit to serving the specialty long term? For investors who backed the company for its cardiac technology, the pivot is a fundamental change in business profile.

The Aviation Bet

The Flyte acquisition suggests that Catheter Precision’s future is in small aircraft operations, not medical devices. Flyte operates regional air routes and is positioning itself in the emerging electric vertical takeoff and landing market. Aviation is capital-intensive and highly regulated, similar to medical devices, but the business model is different — Flyte generates immediate revenue by carrying passengers, whereas Catheter Precision’s medical business was still trying to achieve scale.

It is unclear whether Catheter Precision has the operational expertise or capital depth to succeed in aviation, or whether the Flyte acquisition is a long-term strategic bet or a temporary solution while the company pursues other options.

How to Research Catheter Precision

Catheter Precision files with the SEC under CIK 0001716621. The company’s quarterly filings track revenue, the progress of capital raises, and updates on the strategic advisor’s effort to find a buyer for the cardiac business. The company’s 10-K annual report details the VIVO and LockeT devices, regulatory approvals, the customer pipeline (tracked as “tender wins” or “orders”), and the Flyte acquisition.

The key questions are whether Catheter Precision can successfully divest the cardiac business at a meaningful valuation, and whether the Flyte aviation platform can grow fast enough to sustain the combined company. Neither is assured. Medical device assets in an unsolved market often sell for liquidation prices, not strategic premiums. Aviation is capital-intensive and competitive. The company’s stock reflects these uncertainties.

As with any single security, the shares trade at market prices. The company has FDA approvals and real technology, but unproven commercial traction and an uncertain strategic direction. Nothing here is a recommendation to buy or sell — only a map of what the company currently does and the transitions it is navigating.